- Key facts & figures
- Sanofi share
- News & publications
- Events & presentations
- Corporate governance
- Our publications
- Being a shareholder
- Becoming a shareholder
- Shareholders committee
- US investors
- Regulated information in France
Investor Relations Awards
- Media Releases
- Our sites
- Corporate events
- Press events
- Access to healthcare
- Image Library
- Get to know Sanofi
- Working at Sanofi
- Our Expertise, your future
- Join Sanofi
- Being our partner
- Understanding science discovering
- Developing and marketing innovative solutions
- Manufacturing and supply
- Our company
- R&D innovation
- Our Products
- Our approach
- Improving access to healthcare
- Working together
- Acting ethically
- Preserving the environment
Ensuring sustainable growth
Definitions beginning with the letter A
Adjusted EPS / Business EPS
Adjusted earnings per share is a specific financial indicator that we define as adjusted net income divided by the weighted average number of shares outstanding.
Business earnings per share are defined as business net income divided by the weighted average number of shares outstanding.
Adjusted Net Income / Business Net Income
Adjusted net income is defined as net income attributable to equity holders of the Company determined under IFRS, adjusted to exclude the material impacts of the application of purchase accounting to acquisitions (primarily the acquisition of Aventis) and for certain restructuring costs associated with acquisitions.
Business net income is defined as net income attributable to equity holders of the Company excluding: amortization of intangible assets, impairment of intangible assets, other impacts associated with acquisitions (including impacts of acquisitions on associates), restructuring costs*, gains and losses on disposals of non-current assets*, costs or provisions associated with litigation*, tax effect related to the items listed above as well as effects of major tax disputes.
*Reported in the line items: Restructuring costs and Gains and losses on disposals, and litigation
Sanofi shares are listed on the New York Stock Exchange in the form of American Depositary Receipts (ADRs). One ADR represents one-half of a share. JP Morgan Chase Bank, N.A. sponsors and administers the Sanofi ADR program.
AMF (Autorité des marchés financiers)
The AMF is the French public body responsible for laying down procedural and ethical rules for French financial markets, for overseeing those markets, and for protecting investors and shareholders.
Annual Report on Form 20-F (20-F)
Non-U.S. companies listed in the United States are required to file an “Annual Report on Form 20-F” with the U.S. stock markets authority, the Securities and Exchange Commission (SEC). This document, usually referred to simply as the “20-F”, contains full legal, business and accounting information about a company for the previous financial year. The 20-F must be filed with the SEC within six months of the end of the financial year to which it relates. Sanofi filed its Annual Report on Form 20-F for the year ended December 31, 2013 on March 7, 2014.
The avoir fiscal, a French tax credit associated with dividends, was abolished with effect from January 1, 2005. Since the abolition of the avoir fiscal, the tax regime applicable to dividends has changed.